Who
Thomas L. Harrison
Director
Company insider
Files Form 4 as: Director, Agenus; Director, Acurx Pharmaceuticals; Director, Advanced Flower Capital; Director, Zynerba Pharmaceuticals; Director, Fifth Street Asset Management; Director, Dipexium Pharmaceuticals; Director, Rvue Holdings; Director, Epocrates.
In numbers
- Trades disclosed
- 91
- Buys
- 5
- Sells
- 4
- Bought
- $466K
- Sold
- $3.2M
- Companies
- 10
- Companies where not an officer
- 9
- First trade
- 14 Feb 2006
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | AGEN AgenusBiotechnology | SEC FORM 4 Code A | $31K4,443 at $6.89 | filing |
| 5 Aug 2026filed 11 Aug 2026 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 5 Aug 2026filed 11 Aug 2026 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 Jul 2026filed 7 Jul 2026 | AGEN AgenusBiotechnology | SEC FORM 4 Code A | $31K8,547 at $3.58 | filing |
| 1 Jul 2026filed 7 Jul 2026 | AGEN AgenusBiotechnology | SEC FORM 4 Code A | $31K8,547 at $3.58 | filing |
| 24 Apr 2026filed 28 Apr 2026 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —122,500 at $0.00 | filing |
| 24 Apr 2026filed 28 Apr 2026 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —122,500 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | ACXP Acurx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,150 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | ACXP Acurx Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,150 at $0.00 | filing |
| 1 Apr 2026filed 13 Apr 2026 | AGEN AgenusBiotechnology | SEC FORM 4 Code A | $31K9,228 at $3.32 | filing |
| 1 Apr 2026filed 13 Apr 2026 | AGEN AgenusBiotechnology | SEC FORM 4 Code A | $31K9,228 at $3.32 | filing |
| 2 Jan 2026filed 5 Jan 2026 | AGEN AgenusBiotechnology | SEC FORM 4 Code A | $31K7,691 at $3.98 | filing |
| 2 Jan 2026filed 5 Jan 2026 | AGEN AgenusBiotechnology | SEC FORM 4 Code A | $31K7,691 at $3.98 | filing |
| 20 Nov 2025filed 24 Nov 2025 | AFCG Advanced Flower CapitalConsumer & Specialty Finance | SEC FORM 4 Code A | $15K5,474 at $2.74 | filing |
| 1 Oct 2025filed 3 Oct 2025 | AGEN AgenusBiotechnology | SEC FORM 4 Code A | $29K5,780 at $5.01 | filing |
| 1 Jul 2025filed 15 Jul 2025 | AGEN AgenusBiotechnology | SEC FORM 4 Code A | $26K7,401 at $3.46 | filing |
| 17 Jun 2025filed 15 Jul 2025 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | AGEN AgenusBiotechnology | SEC FORM 4 Code A | $26K8,898 at $2.88 | filing |
| 25 Feb 2025filed 27 Feb 2025 | AFCG Advanced Flower CapitalConsumer & Specialty Finance | SEC FORM 4 Code A | $15K1,792 at $8.37 | filing |
| 7 Aug 2024filed 8 Aug 2024 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
News
Analyzing Futu (NASDAQ:FUTU) and AFC Gamma (NASDAQ:AFCG)AFCG · themarketsdaily.com · 21 Oct 2026TBWA\ Hunt Lascaris celebrates standout Loeries Creative Week - Omnicom Advertising South AfricaOMC · bizcommunity.com · 16 Oct 2026AFC Gamma (NASDAQ:AFCG) vs. Deutsche Boerse (OTCMKTS:DBOEY) Head-To-Head ContrastAFCG · dailypolitical.com · 15 Oct 2026
0 headlines in the last 90 days name Thomas L. Harrison; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.